Midazolam Kalceks (Midazolam)

Midazolam enhances the activity of the neurotransmitter GABA at the GABA‑A receptor, increasing chloride ion flow into neurons. This amplifies inhibitory signaling, leading to decreased neuronal excitability, which produces sedation, anxiolysis, muscle relaxation, and anticonvulsant effects.

The specific dose of Midazolam Kalceks is determined by the prescribing clinician based on the indication, patient age, weight, clinical condition, and route of administration. Healthcare professionals tailor the regimen to achieve the desired therapeutic effect while minimizing adverse reactions.

Safety data for Midazolam in pregnancy and lactation are limited, and the drug is generally classified as contraindicated or used only when the potential benefit outweighs the risk. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Compared with other sedatives such as propofol or dexmedetomidine, Midazolam offers a rapid onset, short duration, and strong anxiolytic and anticonvulsant properties. However, it may cause more pronounced respiratory depression and has a longer recovery time than agents like propofol, making choice dependent on clinical context.

Midazolam Kalceks should be stored at controlled room temperature, below 25 °C, in its original sealed container. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations. Do not freeze the solution, and discard any vial that appears cloudy or contains particles.

Midazolam Kalceks is supplied as a sterile injectable solution and can be given intramuscularly, intravenously, or rectally, depending on the clinical indication. Administration is performed by qualified healthcare personnel using aseptic technique, with dosing adjusted to the patient’s response and monitored continuously.

The most serious risks include severe respiratory depression, profound hypotension, paradoxical reactions such as agitation or seizures, and rare allergic reactions. Continuous monitoring of respiratory and cardiovascular status is essential, especially when used with other depressant drugs or in patients with compromised organ function.

Midazolam is contraindicated in patients with known hypersensitivity to benzodiazepines, severe respiratory insufficiency, acute narrow‑angle glaucoma, or those who are currently intoxicated with alcohol or other CNS depressants. Caution is also advised for individuals with myasthenia gravis, severe hepatic impairment, or a history of severe paradoxical reactions.